Investigational Drug Details
| Drug ID: | D128 |
| Drug Name: | Evogliptin |
| Synonyms: | Evoglitin |
| Type: | Chemical drug |
| DrugBank ID: | DB12625 |
| DrugBank Description: | Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2. |
| PubChem ID: | 25022354 |
| CasNo: | 1222102-29-5 |
| Repositioning for NAFLD: | No |
| SMILES: | C(=O)(C[C@@H](Cc1c(F)cc(c(c1)F)F)N)N1[C@H](COC(C)(C)C)C(=O)NCC1 |
| Structure: |
|
| InChiKey: | LCDDAGSJHKEABN-MLGOLLRUSA-N |
| Molecular Weight: | 401.429 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | DPP4 inhibitor |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 4 completed (NCT03910361) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0054 | NCT03910361 | Phase 4 | Completed | No Results Available | April 12, 2019 | April 29, 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A30847 | 31680767 | Korean J Physiol Pharmacol | Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. | Details |
| A42304 | 34918436 | Diabetes Obes Metab | Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial. | Details |